Palforzia (AR101)

Nestle

Pharma

Palforzia gets new owner as Nestlé ditches peanut allergy drug

Nestlé has resold the peanut allergy drug Palforzia, which it originally bought in 2020 in a $2 billion-plus acquisition.

Angus Liu Sep 5, 2023 11:20am

Peanuts in shell

Nestlé lays out $2.1B for peanut allergy drugmaker Aimmune

Aug 31, 2020 10:27am

Peanuts in shell

With FDA nod, Aimmune aims to prove Palforzia doubters wrong

Feb 3, 2020 8:46am